Firvanq FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved January 26, 2018)
Brand name: Firvanq
Generic name: vancomycin hydrochloride
Dosage form: for Oral Solution
Company: CutisPharma
Treatment for: Clostridioides difficile Infection, Enterocolitis
Firvanq (vancomycin hydrochloride) is an oral solution formulation of an approved tricyclic glycopeptide antibiotic for the treatment of Clostridium difficile associated diarrhea and Staphylococcus aureus enterocolitis.
Development timeline for Firvanq
| Date | Article |
|---|---|
| Jan 29, 2018 | Approval CutisPharma Announces FDA Approval of Firvanq (vancomycin) for Treatment of Clostridium Difficile Associated Diarrhea and Staphylococcus Aureus Colitis |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.